HERON THERAPEUTICS, INC. /DE/ Stockholders Equity

Quick Answer

HERON THERAPEUTICS, INC. /DE/ reported Stockholders Equity of $14.33 million for fiscal year 2025.

HERON THERAPEUTICS, INC. /DE/ Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $14.33M +142.6%
2024 -$33.65M +0.9%
2023 -$33.97M -350.3%
2022 $13.57M -82.5%
2021 $77.57M -67.2%
2020 $236.49M -41.4%
2019 $403.83M +9.1%
2018 $370.16M +182.3%
2017 $131.14M +717.1%
2016 -$21.25M -118.0%
2015 $118.11M +87.3%
2014 $63.06M -8.5%
2013 $68.94M +33.1%
2012 $51.82M +229.0%
2011 $15.75M +1097.0%
2010 $1.32M -80.6%
2009 $6.80M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $14.88M +137.2% +154.6%
June 30, 2025 -$27.26M +28.2% +4.2%
March 31, 2025 -$28.45M +15.7% +15.4%
December 31, 2024 -$33.65M +0.9% +15.9%
September 30, 2024 -$40.01M -44.0% -5.4%
June 30, 2024 -$37.94M +3.4% -12.4%
March 31, 2024 -$33.77M -195.4% +0.6%
December 31, 2023 -$33.97M -350.3% -22.3%
  • HERON THERAPEUTICS, INC. /DE/ showed an increase of +142.6% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2009–2025 period, HERON THERAPEUTICS, INC. /DE/’s stockholders equity has grown by 110.9% (from $6.80 million to $14.33 million).
  • The most recent figure is from HERON THERAPEUTICS, INC. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment